e17533 Background: Platinum-based regimens are standard of care in advanced lung cancer despite low response rates. They damage DNA by forming platinum-DNA adducts. Tumor expression of ERCC1, a key enzyme in nucleotide excision repair, may predict the response to platinum agents with increased expression associated with resistance. We examined if combined impairment of two DNA repair pathways, PARP inhibition and low ERCC1 expression, would increase sensitivity to platinum agents in lung cancers. Methods: Cell viability and cell cycle effects were measured using MTS, clonogenic and BrdU proliferation assays. ERCC1 expression and phosphorylation of P53 and γH2A were determined by Western blots. Knockdown was performed using siRNA pools targeting ERCC1. All data were expressed as means ± SD from at least triplicates. Statistical analysis was performed by one- or two-way ANOVA. Results: A549, H157 lung cancer cells have high ERCC1 expression, whereas HCC827, PC9 have low expression. When different dose-combinations of cisplatin and olaparib (PARP inhibitor) were tested, olaparib selectively augmented cisplatin-induced growth inhibition in ERCC1-low but not in ERCC1-high cells. As a single agent, olaparib conferred selective cytotoxicity against ERCC1-low cells with no effects in ERCC1-high cells. Knockdown of ERCC1 in ERCC1-high A549 significantly increased sensitivities to olaparib and cisplatin. Treatment with cisplatin or olaparib led to an increase in the G2/M population in ERCC1-low cells with an even stronger effect seen with the combination. Cisplatin and olaparib activated DNA damage pathways as evidenced by increased phospho-γH2A levels. Olaparib and cisplatin alone or in combination increased phospho-P53 in ERCC-low HCC827 cells in a dose-dependent fashion. Conclusions: PARP inhibition selectively augments cisplatin sensitivity in ERCC1-low but not high lung cancer cells. Cisplatin sensitivity is enhanced by ERCC1 knockdown in ERCC1-high cells. PARP inhibition alone or in combination with cisplatin leads to G2/M cell cycle arrest, likely by activation of the pathway involving γH2A and P53. Our study may identify novel synergistic approaches based on synthetic lethality for lung cancer based on tumor ERCC1 expression.